Stability in the production and transport of 177Lu labelled PSMA

Cristian Antonio Wieczorek Villas Boas; Luís Alberto Pereira Dias; Margareth Mie Nakamura Matsuda; Elaine Bortoleti de Araújo

doi:10.15392/bjrs.v9i1.1619

Authors

Cristian Antonio Wieczorek Villas Boas Radiopharmacy CenterNuclear and Energy Research Institute - IPEN/USP https://orcid.org/0000-0003-0048-4749
Luís Alberto Pereira Dias
Margareth Mie Nakamura Matsuda
Elaine Bortoleti de Araújo

DOI:

https://doi.org/10.15392/bjrs.v9i1.1619

Keywords:

production of 177Lu-PSMA-617, radiopharmaceutical stability, industrial radiopharmacy center.

Abstract

The prostate cancer is the second most prevalent disease among men in Brazil, moreover PSMA therapy could change this scenario and its perspectives. IPEN-CNEN is the Brazilian industrial radiopharmacy center that produces radiopharmaceuticals for therapy. The production of ¹⁷⁷Lu-PSMA-617 was evaluated in batches until 37 GBq and showed that the combination of ascorbate buffer, adequate radioactive concentration and freezing promoted the stability of the radiopharmaceutical for 48 hours, enabling transport of ¹⁷⁷Lu-PSMA-617 to distant regions of the country.

Views: 823
PDF Downloads: 435

Downloads

Download data is not yet available.

Author Biography

Cristian Antonio Wieczorek Villas Boas, Radiopharmacy CenterNuclear and Energy Research Institute - IPEN/USP

Atualmente aluno de doutorado do Programa de Pós-Graduação do IPEN-CNEN/SP (bolsa FAPESP 2018/12965-4), que tem como objetivo principal realizar estudos de scale-up para futura produção do PSMA-617 radiomarcado com lutécio-177, bem como auxiliar na documentação necessária para peticionamento de ensaio clínico deste radiofármaco junto à ANVISA. Graduado em Farmácia pela Faculdade Oswaldo Cruz (2010), Mestre em Farmácia pela Universidade Anhanguera de São Paulo (2013), especialista em Gestão Empresarial pelo SENAC (2016). Atuou como professor no curso de pós-graduação no curso de Farmácia Clínica nas Faculdades Oswaldo Cruz (2014-2015). Possui experiência na área de Farmácia, com ênfase em farmacotécnica, síntese orgânicas e radiofarmácia. Atualmente é membro da Comissão Assessora de Radiofarmácia pelo Conselho Regional de Farmácia do Estado de São Paulo.

References

INCA. INSTITUTO NACIONAL DO CÂNCER. Câncer de próstata. Disponível em: <https://www.inca.gov.br/tipos-de-cancer/cancer-de-prostata>. Acesso em: 17 jun. 2020.

LIU, S.; ELLARS, C.E.; EDWARDS, D.S. Ascorbic acid: Useful as a buffer agent and radiolytic stabilizer for metalloradiopharmaceuticals. Bioconjugate Chemistry, v. 14, n. 5, p. 1052–1056, 2003.

MAUS, S. et al. Aspects on radiolabeling of 177Lu-DOTA-TATE: After C18 purification re-addition of ascorbic acid is required to maintain radiochemical purity. International Journal of Diagnostic Imaging, v. 1, n. 1, p. 5, 2014.

REILLY, R.M. Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2010.

AGENCIA NACIONAL DE VIGILÂNCIA SANITÁRIA. Resolução da Diretoria Colegiada - RDC No 301, de 21 de agosto de 2019. Disponível em: <http://portal.anvisa.gov.br/documents/10181/5389382/RDC_301_2019_.pdf/2e049461-1e8a-4bbb-8e09-8d3c04dea07d>. Acesso em: 5 jan. 2020.

BREEMAN, W.A.P. et al. The addition of DTPA to[177Lu-DOTA0, Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity. European Journal of Nuclear Medicine and Molecular Imaging, v. 30, n. 2, p. 312–315, 2003.

PRICE, E.W.; ORVIG, C. Matching chelators to radiometals for radiopharmaceuticals. Chemical Society Reviews, v. 43, n. 1, p. 260–290, 2014.

BREEMAN, W.A.P. et al. Overview of Development and Formulation of 177 Lu-DOTA-TATE for PRRT. Current Radiopharmaceuticals, v. 9, n. 1, p. 8–18, 23 nov. 2015.

DE ZANGER, R.M.S. et al. Maintaining radiochemical purity of [177Lu]Lu-DOTA-PSMA-617 for PRRT by reducing radiolysis. Journal of Radioanalytical and Nuclear Chemistry, v. 321, n. 1, p. 285–291, 2019.

WAHL, R.L. et al. Inhibition of autoradiolysis of radiolabeled monoclonal antibodies by cryopreservation. Journal of Nuclear Medicine, v. 31, n. 1, p. 84–89, 1990.